Quick Answer
Sagimet Biosciences Inc. reported Diluted EPS of $1.58 per share (loss) for fiscal year 2025.
Sagimet Biosciences Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.58 | -9.0% |
| 2024 | -$1.45 | +45.5% |
| 2023 | -$2.66 | +98.4% |
| 2022 | -$165.20 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | +11.1% | -25.0% |
| June 30, 2025 | -$0.32 | -28.0% | +42.9% |
| March 31, 2025 | -$0.56 | -143.5% | -24.4% |
| September 30, 2024 | -$0.45 | -28.6% | -80.0% |
| June 30, 2024 | -$0.25 | +99.3% | -8.7% |
| March 31, 2024 | -$0.23 | +99.4% | +34.3% |
| September 30, 2023 | -$0.35 | +99.1% | +99.0% |
| June 30, 2023 | -$35.80 | +6.7% | -0.6% |
- Sagimet Biosciences Inc. showed a decrease of -9.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Sagimet Biosciences Inc.’s diluted eps has grown by 99.0% (from $165.20 per share (loss) to $1.58 per share (loss)).
- The most recent figure is from Sagimet Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: